Abliva‘s objective is to design pharmaceuticals that preserve the integrity and function of mitochondria for indications where there is a great unmet medical need. Abliva is continuously engaged in the vibrant mitochondrial science community as well as the world of investors and potential partners.
Redeye’s Orphan drugs, 27 May 2020
CEO presentation at the Annual General Meeting 2020
Lund, Sweden, on 20 May 2020.
Redeye Digital Investor Forum, 31 March, 2020.
Erik Penser Bank Bolagsdag, 12 March, 2020, Stockholm, Sweden.
Stockholm Corporate Finance 12th Life Science seminar, 11 March, 2020.
Aktiespararna’s Aktiedagen Lund, 28 January 2020, Lund, Sweden.